Advancements in Rheumatoid Arthritis: Shifting Focus to Prevention
Rheumatoid arthritis (RA) impacts over 18 million individuals globally, including approximately 1.5 million in the United States. This autoimmune, inflammatory condition causes the immune system to attack joints, leading to a range of debilitating symptoms such as pain, stiffness, swelling, fatigue, and flu-like sensations.
Untreated RA can result in joint damage and significant disability, hindering daily activities.
Historically, RA has been treated only after the onset of symptoms. However, current research indicates a potential for earlier identification and prevention of the disease. Physicians specializing in RA and researchers are actively working towards identifying individuals at risk before RA fully develops and exploring treatments to delay or prevent its progression.
Uncovering the Preclinical Stage
Current diagnosis involves examining swollen joints and testing for blood markers known as autoantibodies. Key autoantibodies include rheumatoid factor and anti-cyclic citrullinated peptide, which are present in up to 80% of RA cases.
Studies have confirmed a preclinical stage of RA, lasting three to five years or more. During this stage, these autoantibodies are detectable in the blood prior to joint swelling. Autoimmunity is present, but organ function remains normal, and individuals may not experience symptoms.
Identifying At-Risk Individuals
The identification of this preclinical stage allows healthcare providers to use markers like autoantibodies and symptoms such as prolonged early morning joint stiffness to identify at-risk individuals before joint inflammation begins. While predicting future RA is still in the research phase, efforts are underway to establish routine testing methods, similar to cholesterol level assessments for cardiovascular disease risk.
The Promise of Preventive Treatments
Ongoing research focuses on developing treatments to delay or prevent full RA. Trials have involved individuals positive for anti-cyclic citrullinated peptide or those with other risk factors, including joint pain and subclinical joint inflammation detected through imaging.
These trials have utilized immune drugs commonly used for established RA, such as methotrexate, hydroxychloroquine, and rituximab. Researchers are investigating if short courses of these drugs can induce a lasting immune system reset and prevent RA development. While no preventive drug is yet approved, these studies offer promise for future interventions.
Deepening Our Understanding of Early RA Biology
Challenges remain in understanding the biology of the preclinical stage. Historically, studies concentrated on patients with established arthritis. However, the use of blood markers like anti-cyclic citrullinated peptide antibodies now enables easier identification of at-risk individuals, leading to increased research into the early biology of RA. It is now understood that the preclinical stage involves multiple abnormalities in the immune system, including cells, autoantibodies, and inflammation. Researchers aim to find interventions that target these immune system dysfunctions before joint swelling occurs.
The Mucosal Origins Hypothesis
An emerging theory, the mucosal origins hypothesis, suggests that early RA autoimmunity originates at mucosal surfaces like the gums, lungs, and gut, with joint involvement occurring later. This hypothesis could explain the links between periodontal disease, lung conditions, exposure to tobacco or smoke, and specific bacteria as RA risk factors. Further research into this area could inform targeted interventions.
Challenges and Future Directions
Despite the strong predictive value of biomarkers like anti-cyclic citrullinated peptide antibodies, a challenge is that some positive individuals do not develop full RA.
Approximately 20% to 30% of people with these antibodies develop RA within two to five years, though specific combinations of risk factors can elevate this to over 50% within one year. This variability complicates recruitment for prevention clinical trials. Researchers have primarily recruited individuals presenting with early joint symptoms but no swollen joints. To expand prevention trials, larger, international networks are needed to screen for risk factors in the broader population. The field continues to advance towards making RA prevention a part of routine clinical care.